OOIR: Observatory of International Research

Papers

(The TQCC of Journal of the Peripheral Nervous System is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision	255
COVID‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era	51
Guillain‐Barré syndrome associated with SARS‐CoV‐2 infection: A systematic review and individual participant data meta‐analysis	47
The neuropathy in hereditary transthyretin amyloidosis: A narrative review	46
Platinum accumulation in oxaliplatin‐induced peripheral neuropathy	29
Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel‐induced peripheral neurotoxicity in breast cancer patients	28
Small and large fiber sensory polyneuropathy in type 2 diabetes: Influence of diagnostic criteria on neuropathy subtypes	26
Guillain‐Barré syndrome decreases in Singapore during the COVID‐19 pandemic	20
A longitudinal and cross‐sectional study of plasma neurofilament light chain concentration in Charcot‐Marie‐Tooth disease	20
Loss of function MPZ mutation causes milder CMT1B neuropathy	18
Recent advances in the treatment of Charcot‐Marie‐Tooth neuropathies	17
Cutaneous and muscular afferents from the foot and sensory fusion processing: Physiology and pathology in neuropathies	15
Acute and chronic inflammatory neuropathies and COVID‐19 vaccines: Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP)	15
The Hippo pathway: Horizons for innovative treatments of peripheral nerve diseases	14
The diagnostic accuracy of the small fiber neuropathy symptoms inventory questionnaire (SFN‐SIQ) for identifying pure small fiber neuropathy	14
Report of a fulminant anti‐pan‐neurofascin‐associated neuropathy responsive to rituximab and bortezomib	14
Antecedent infections in Guillain‐Barré syndrome in endemic areas of arbovirus transmission: A multinational case‐control study	13
Antecedent infections inGuillain‐Barrésyndrome patients from south India	13
Acute small fiber neuropathy after Oxford‐AstraZeneca ChAdOx1‐S vaccination: A report of three cases and review of the literature	12
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome	12
Charcot–Marie–Toothneuropathies: Current gene therapy advances and the route toward translation	12
Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin‐related amyloidosis—A Swiss reference center experience	11
Acute nitrous oxide‐induced neuropathy mimicking Guillain‐Barré syndrome	10
Associations of Guillain‐Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database	10
Anxiety and depression in small fiber neuropathy	10

Impact of drug formulations on kinetics and toxicity in a preclinical model of paclitaxel‐induced neuropathy	10
Long read sequencing overcomes challenges in the diagnosis of SORD neuropathy	10
Liver‐directed drugs for transthyretin‐mediated amyloidosis	9
Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS)	9
Hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE‐CIDP 1 randomized controlled tria	9
Sensory neuronopathies: A case series and literature review	9
Wearables, sensors, and smart devices for the detection and monitoring of chemotherapy‐induced peripheral neurotoxicity: Systematic review and directions for future research	8
Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first‐line therapy	8
A prospective study on surgical management of foot deformities in Charcot Marie tooth disease	8
Current profile of Charcot‐Marie‐Tooth disease in Africa: A systematic review	8
Proximal weakness involvement in the first Italian case of Charcot‐Marie‐Tooth 2CC harboring a novel frameshift variant in NEFH	8
Focal chronic inflammatory demyelinating polyradiculoneuropathy: Onset, course, and distinct features	8
Variants of aminoacyl‐tRNA synthetase genes in Charcot‐Marie‐Tooth disease: A Korean cohort study	8
Charcot‐Marie‐Tooth disease: Genetic profile of patients from a large Brazilian neuromuscular reference center	7
Frequency dependent, reversible focused ultrasound suppression of evoked potentials in the reflex arc in an anesthetized animal	7
Description of a patient cohort with Hereditary Sensory Neuropathy type 1 without retinal disease Macular Telangiectasia type 2 ‐ implications for retinal screening in HSN1	7
ABSTRACT	7
Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands	7
Variations within Toll‐like receptor (TLR) and TLR signaling pathway‐related genes and their synergistic effects on the risk of Guillain‐Barré syndrome	7
Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment response	6
SARM1 knockout does not rescue neuromuscular phenotypes in a Charcot‐Marie‐Tooth disease Type 1A mouse model	6
VitaminB6levels do not correlate with severity of neuropathy in chronic idiopathic axonal polyneuropathy	6
The endogenous calpain inhibitor calpastatin attenuates axon degeneration in murineGuillain‐Barrésyndrome	6
Severe distinct dysautonomia in RFC1‐related disease associated with Parkinsonism	6
Autoimmune nodo‐paranodopathies 10 years later: Clinical features, pathophysiology and treatment	6
Comorbidities, anthropometric, demographic, and lifestyle risk factors for ulnar neuropathy at the elbow: A case control study	6
Benefit of high‐dose oral riboflavin therapy in riboflavin transporter deficiency	6
Comparing neuropathy in multiple myeloma and AL amyloidosis	6
An approach to assessing immunoglobulin dependence in chronic inflammatory demyelinating inflammatory polyneuropathy	5
Neutrophil‐lymphocyte ratio in Guillain‐Barré syndrome: A prognostic biomarker of severe disease and mechanical ventilation in Bangladesh	5
Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post‐hoc analysis of the immunoglobulin overtreatment in CIDP trial	5
Electrodiagnostic subtyping in Guillain‐Barré syndrome: Use of criteria in practice based on a survey study in IGOS	5
Clinical and serological prognostic factors in childhoodGuillain‐Barrésyndrome: A prospective cohort study in Bangladesh	5
A new de novo SYT2 mutation presenting as distal weakness. Neuropathy or neuromuscular junction dysfunction?	5
Techniques for the standard histological and ultrastructural assessment of nerve biopsies	5
Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin‐induced peripheral neurotoxicity	5
Validation of an Artificial Intelligence driven framework to automatically detect red flag symptoms in screening for rare diseases in electronic health records: hereditary transthyretin amyloidosis po	5
An innovative phase 2 proof‐of‐concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy	5
Plasma neurofilament light chain concentrations are elevated in youth‐onset type 2 diabetes and associated with neuropathy	5
The epidemiology of Guillain‐Barré syndrome in Thailand over 13 years (2005‐2017): A nationwide population‐based retrospective cohort study	5
Targeting translation: A review of preclinical animal models in the development of treatments for chemotherapy‐induced peripheral neuropathy	5
Identical late motor responses in early Guillain‐Barré syndrome: A‐waves and repeater F‐waves	4
2021 Peripheral Nerve Society virtual event	4
Unusual upper limb features in SORD neuropathy	4
Predicting long‐term trends in inflammatory neuropathy outcome measures using latent class modelling	4
Validation of a new hand function outcome measure in individuals with Charcot‐Marie‐Tooth disease	4
Utility of stimulus induced after discharges in the evaluation of peripheral nerve hyperexcitability: Old wine in a new bottle?	4
Axolemmal nanoruptures arising from paranodal membrane injury induce secondary axon degeneration in murine Guillain‐Barré syndrome	4